


AICR

*Cancer knows no boundaries.
Fortunately, neither do we.*



Legal and administrative details

Vice-Presidents

The Earl of Elgin and Kincardine, KT, CD, LLD, JP
Sir James Black, OM, FRS, FRSE, FRCP
Mr Donald Findlay, QC
Mr Charles Miller Smith
Lord Steel of Aikwood, KT, KBE, PC, DL

Executive Board of Directors

Mr James Murray (Chairman)
Professor C Simon Herrington
Mr John F Matthews OBE
Mr James Ogilvy
Mr Andrew Orme
Professor C Michael Steel
Mrs Maureen Thomson
Professor John A Wyke

Chief Executive

Mr Norman Barrett

Company Secretary

Mr Douglas W Gunstone

Solicitors

Murray Donald Drummond Cook LLP
Kinburn Castle
St Andrews
KY16 9DR

Bank

The Royal Bank of Scotland
South Street
St Andrews
KY16 9QB

Auditors

Henderson Loggie Chartered Accountants
Royal Exchange
Dundee
DD1 1DZ

Investment advisors

Sarasin and Partners LLP
Juxon House
100 St Paul's Churchyard
London
EC4M 8BU

Registered office

Madras House
St Andrews
Fife
KY16 9EH

Tel: 01334 477910
Fax: 01334 478667
E-mail: aicr@aicr.org.uk
Website: www.aicr.org.uk

Registered in Scotland, no: 152991
Charity no. SC022918

Contents

About AICR	1
Map of projects	2
Chairman's comments	3
Chief Executive's comments	4
Scientific successes from the past year	5 & 6
New research projects funded by AICR	7 & 8
Raising money for research	9
- Regular giving	9
- Donations from competitions & raffles	9
- Other fundraising (events and online fundraising)	9 & 10
Corporate support, trusts and payroll giving	11
30th anniversary scientific conference	12
Financial accounts	13 & 14
Thank you	15
Legacies	16

About cancer

Cancer now affects one in three of our loved ones and each year around 12.5 million people are diagnosed with cancer worldwide. Although cancer can occur at any age it is most common in older people. Around three-quarters of cases occur in people aged 60 and over and only around one per cent of cancers occur in children, teenagers and young adults (up to the age of 24). The good news is that survival rates have doubled in the past forty years and half of those diagnosed with cancer now survive their disease for more than five years. However, with around 7.5 million people still dying from cancer worldwide each year there is much that needs to be done to help prevent, diagnose and treat this terrible disease.

About AICR

Who are we?

AICR (Association for International Cancer Research) funds vital cancer research around the world. Our best hope for more people to be cured of cancer, and more lives saved, is through improvements in prevention, diagnosis and treatment. These advances can only be made tomorrow, by investing in research today; that is why AICR supports the very best cancer research proposals it receives, wherever in the world the projects take place.

What do we do?

We award funding to leading cancer researchers around the world. AICR invites applications for funding twice a year, in April and October. Our Scientific Advisory Committee (SAC), which is made up of international cancer research experts who give their time voluntarily, helps us decide which applications are of the highest quality. The applications undergo an extremely rigorous review process, using more experts from around the world, which assists our SAC in deciding which projects should be funded. For every project we currently fund there is another equally worthy that we simply cannot afford.

Why is AICR different from other cancer charities?

The main difference is our willingness to fund research anywhere in the world. Cancer is a worldwide problem and therefore requires a worldwide effort if we want to make real progress. AICR funds both prominent and promising scientists as we believe investing in the future of science is essential. We only award grants for research projects of up to three years and the funds we raise are spent solely on the expert scientific teams and their supplies. We do not employ scientists or run laboratories, instead we award grants to scientists working at leading research institutes and universities, meaning that we can maximise the funds spent on cancer research. As we are not tied to specific research programmes, AICR has the freedom to support innovative projects into less well-funded areas of cancer research.

At the end of this financial year we are currently funding 246 projects in 25 countries at a cost of over £42 million. To date we have invested more than £142 million into cancer research on 1,762 projects in 32 different countries. This has all been raised by generous donations from our supporters.

Over the last year we have awarded 49 grants, totalling over £9 million, including a 6 year fellowship to a very promising new independent researcher.

Here is a world map showing the countries in which these new projects are being carried out and the number we funded in each one.





James Murray - Chairman

Chairman's comments

I am delighted to report that despite a testing economic climate our results for the year are very much on target with income at £17.5m against a budgeted figure of £17.7m. This means that AICR is able to offer a fellowship and grants of £8.7m to leading cancer scientists throughout the world with a further £1.8m being spent on education. This is a very satisfactory outcome given the extremely difficult financial world in which we have had to operate.

Our income, unlike many charities, has stood up very well in these challenging times, thanks in large measure to our loyal and generous supporters both here in the United Kingdom and throughout the world. It is through their commitment to AICR that we have been able to continue the same level of support to cutting edge scientific cancer research and on behalf of all at AICR I should like to thank them for their generosity.

You will read in the next few pages about some of the exciting projects which our donors' money supports. These projects have been selected by AICR's Scientific Advisory Committee, a body which comprises of leading cancer specialists throughout Europe, and whose mission is to select only projects which reflect the very best science. It is hoped that from this research and these projects further breakthroughs will be made into our understanding of cancer and the causes of it. Our Scientific Advisory Committee carries out this work voluntarily and without payment. It is a large commitment on their part and we at AICR owe them a great debt of gratitude.

Sadly I report that in March this year one of our Vice-Presidents, Sir James Black, OM, FRS, FRSE, FRCP, died. Born in Lanarkshire, Scotland, Sir James Black was an eminent academic and researcher who strongly endorsed the work funded by AICR. During his career he developed the world's bestselling

drug, propranolol, a beta blocker which is used as a treatment for heart disease and cimetidine (Tagamet), a drug used to treat stomach ulcers. He was knighted in 1981 and received the Nobel Prize for Medicine in 1988 for his work on these two drugs. We are grateful for his support over the years and he will be much missed.

During the year AICR enjoyed its 30th Anniversary and this was celebrated with an Anniversary Conference in St Andrews which you can read about in more detail on page 12.

We have also continued to explore fundraising opportunities overseas. This is important for AICR as an international charity which supports the best science wherever that may be. I hope to be able to report more fully on this in next year's Review.

At home we are pursuing our goal of increasing our income from legacies with a major new legacy development campaign. This initiative has been recognised by the Institute of Fundraising with an award to our Chief Executive, Norman Barrett and our Legacy Manager, Geraldine Long, for AICR's innovative campaign.

Lastly, I should like to thank all those who have supported AICR during this past year and whose support is vital to the AICR's continuing success - to our donors whose generosity constantly surprises us, to our Scientific Advisory Committee whose expertise is essential in determining which science should be supported, to our loyal and committed staff and to my Board of Directors, who give so generously of their time and advice.

James Murray
Chairman



Norman Barrett - Chief Executive

Chief Executive's comments

As our chairman has mentioned, in 2010 we reached our 30th anniversary, culminating in our successful conference which you can read about later on in our Review. Thanks to our generous supporters in that time, from one small office in St Andrews, AICR has funded more than 1700 cancer research projects, in 32 different countries and spent more than £142 million. Since the early 1970's the overall ten-year survival rates for cancer have doubled and cancer research, like that funded by AICR, has been at the heart of this. I found myself looking back with great pride that I have been able to be part of this progress and want to thank everyone who has supported AICR in any way over these past 30 years.

Despite what has been happening in the economy, AICR has continued to promote, conduct and support research into the causes, prevention, diagnosis and treatment of cancer around the world as set out in our research strategy. We have also noticed that in recent years, more and more of our grants have been going to fund research projects abroad and we are now actively looking at how we can exploit opportunities in other parts of the world to raise money in the near future.

No doubt as a result of the current economic situation, and as governments introduce cuts in many areas, we are seeing more and more applications for funding coming in to AICR. I want to acknowledge and warmly thank the hard-working and dedicated volunteers on our Scientific Advisory Committee who give up huge amounts of their time to appraise and scrutinise our grant applications, so that only the best projects receive funding.

Despite what has clearly been a difficult time for everyone, thanks to the support of our donors, we have managed to maintain our level of funding over the last year. In recognition of this vital support, we have adopted a policy of thanking our donors in a special DVD which also explains how we allocate grants and emphasises how careful we are about spending the money we receive. If you haven't yet received a copy and would like one, please call the office and we will be delighted to let you have one.

This year we have tried to look at ways of enabling our donors to hear from the scientists they are supporting. Staff have been filming interviews of the scientists and posting them on AICR's website. We are also working to make lab visits more available to our donors so that they can see, first-hand, how the scientists are using their donations.

In addition to our website, we continue to use social media to engage with our fundraisers and supporters. We now enjoy a considerable amount of dialogue with them through Twitter and Facebook and also on YouTube. I find it really encouraging to know that they are taking the trouble to find out about our work in this way.

As I reflect on how far we have come over the years and what an almost insurmountable challenge it may have seemed 30 years ago, I look forward to climbing another mountain and one which has a personal significance for me. Our fundraisers never cease to amaze me with their dedication and inventiveness and we are constantly trying to come up with new and innovative ideas to inspire them. This year I think we have surpassed ourselves. Our first-ever Kilimanjaro trek is being trialled in 2011 and I have been persuaded to get fit and take part. Surely my own biggest challenge to date.

However, when I think of the efforts of all our staff, volunteers, Board members and fundraisers, it will be a privilege to take AICR to the top of Africa's highest mountain. The only way is up!

Norman Barrett
Chief Executive

Scientific successes from the past year

Donations from our generous supporters are helping to make a difference in the fight against cancer. Below are some examples of AICR funded researchers, the cutting-edge projects they have undertaken and the amazing progress being made thanks to our donors.

New hope for breast cancer patients

Professor Clare Isacke, University College London, UK - AICR grant: £194,895

More than a million women are diagnosed with breast cancer worldwide every year and it accounts for one in ten of all new cancers. Many breast cancers require the female sex hormone oestrogen in order to grow. The oestrogen turns on a protein called the oestrogen receptor and so these types of breast cancers are described as: 'hormone sensitive' or 'hormone receptor positive'. They can be treated with drugs that block the effects of oestrogen, such as tamoxifen. However, some breast cancers are resistant to this drug, or can develop resistance over time, allowing the cancer to recur or continue growing. Professor Isacke's discovery, funded by AICR and Breakthrough Breast Cancer, could lead to new drugs that counteract this resistance which causes major problems for patients.

Her findings showed that when another protein called RET is switched on, it can turn on the oestrogen receptor even in the absence of any oestrogen. They also found tissue samples from oestrogen positive breast cancer patients had increased levels of RET. They went on to show that reducing the levels of RET actually made the breast cancer cells more sensitive to tamoxifen, and more likely to die. Professor Isacke said: "We are very excited by these findings. Our challenge now is to work out how RET turns on the oestrogen receptor so that we can develop new treatments for tamoxifen-resistant breast cancers"

Understanding how cancer spreads

Professor Jonathan Sleeman, Heidelberg University, Germany - AICR grant: £105,300

Cancer is such a deadly disease because of its ability to spread around the body and invade the vital organs. Professor Sleeman recently found that a molecule called ASAP1 plays a key role in how cancer spreads. He and his colleagues discovered that ASAP1 was amongst a group of molecules whose levels were increased in breast and pancreatic cancer cells that had started to spread. To investigate whether this molecule is involved in the actual cause of the spread, the team made pancreatic cancer cells with high and low levels of ASAP1. They discovered that cells with high ASAP1 spread much faster than cells with lower levels, and therefore ASAP1 was probably the cause of the more rapid spread of this cancer. Further findings led them to believe it may be possible to develop drugs that stop cancer cells from spreading to other parts of the body. Drugs developed from studies like this could become an important new way to treat cancer.

Investigating the involvement of trace metals in bladder cancer

Dr Núria Malats, Spanish National Cancer Centre, Spain - AICR grant: £151,522

Worldwide, an estimated 356,600 new cases of bladder cancer are diagnosed each year and it is the seventh most common cancer in the UK. There are several risk factors already linked to bladder cancer, the biggest being smoking, exposure to environmental tobacco smoke during childhood, age and occupational exposure to certain chemicals, particularly in countries with less regulated industrial processes.

By contrast, selenium is considered to be an antioxidant and high levels have been linked to a decreased risk of several cancer types, including stomach and lung, but its link to bladder cancer was unknown.

To address this question a meta-analysis study, using the combined data from seven studies to give more accurate results, was carried out by Dr Núria Malats at the Spanish National Cancer Research Centre in Madrid. Dr Malats and her team examined the levels of selenium in blood serum and toe nail cuttings and analysed the risk of bladder cancer.

The work was funded by several grants including one from the Association for International Cancer Research (AICR) and the results showed that a high selenium intake does indeed reduce bladder cancer risk. They found the decreased risk was mainly among women, which may be due to differences in the way the genders accumulate and excrete selenium.

Dr Malats said that 'although these findings suggest a protective effect of selenium for bladder cancer risk, additional large studies would be required to support these findings.'

New hope for improved cervical cancer screening

Dr Daniel Ndisang, University College London, UK - AICR grant: £189,352

Dr Daniel Ndisang has recently discovered a potential new screening method for cervical cancer which could be more effective than the current one.

"Across the world, half a million women are diagnosed with cervical cancer every year, most of them in developing countries. In developed countries screening helps to prevent around 75% of cases by detecting it early, when treatment is most successful. Yet cervical cancer still accounts for about one in 10 female cancer deaths worldwide" he explained. "The best hope to save women dying from cervical cancer is to have cheap and effective screening methods which can be used in developing countries and we hope our findings might lead the way to develop such programmes."

The team found that a molecule called Brn-3a is present at high levels in both cervical cancer and pre-cancer lesions. These include the rarer types which are difficult to diagnose using the current screening procedures and therefore have lower survival rates. Brn-3a is known to switch on the molecule E6 which is found in the human papillomavirus (HPV), the main risk factor and a cause of cervical cancer.

These findings suggest that, by measuring the levels of both the Brn-3a and E6 molecules, more women with the early stages of cervical cancer could be diagnosed and treated, and more lives could be saved. Importantly, measuring these molecules is much cheaper than the current screening procedures and could therefore help reduce the deaths from cervical cancer across the globe.



New research projects funded by AICR

During 2009/10 AICR awarded 49 grants, totalling over £9 million, to researchers all around the world. Here are some examples of the work our donors helped fund:

Is cholesterol a risk factor for prostate cancer?

Dr Michelle Hill, University of Queensland, Australia - AICR grant: £172,742 for 3 years

Recent research found that severely overweight men have a greater risk of getting prostate cancer. The initial findings suggest that high blood cholesterol may also increase the risk but how these conditions are linked remains unclear. To investigate this, Dr Hill is focusing on the role of two molecules called caveolin-1 and cavin-1. "There are several reasons I am looking at these molecules" Dr Hill told us "firstly, they are on the surface of the cells to which cholesterol sticks and secondly, prostate tumours with higher levels of caveolin-1 are more likely to be aggressive tumours which reoccur after treatment. This suggests that these molecules, along with cholesterol, may be involved in the spread of prostate cancer."

Dr Hill will be analyzing the levels of caveolin-1 and cavin-1 in a series of prostate cancer tissue samples. She will also study how these molecules interact with cholesterol on the surface of prostate cancer cells and how this affects the ability of the cells to spread. Dr Hill's project should give us a better insight into the role of cholesterol in prostate cancer and her findings may also help tell us whether cholesterol-lowering drugs could be used to reduce the risk of cancer.

Understanding why bowel cancer develops

Dr Frederik Hes, Leiden University Medical Centre, The Netherlands - AICR grant: £200,000 for 3 years

Almost all cases of bowel cancer develop from polyps: small growths that can occur inside the bowel. Dr Hes is trying to discover the genes which make a normal polyp turn into early bowel cancer. He explains "there are a few people who inherit a very high risk of getting bowel cancer but these account for only a tiny minority of bowel cancer cases. In recent years scientists have been finding that small variations in certain 'lower-risk' genes also seem to increase or decrease a person's risk of certain cancers. These are the ones we are trying to identify." Dr Hes is collaborating with a number of researchers across Europe. Together they will collect blood samples from about 500 people with polyps in order to analyse their DNA to identify changes which are associated with the polyps. Once the genes are identified the team will do further research to investigate the role they play in causing bowel cancer. Identifying such 'low-risk' bowel cancer genes will help predict a person's risk of getting this type of cancer. In the future this may help identify those who could need to take extra preventative steps or medication to reduce their chance of getting bowel cancer.

Defining the relationship between ovulation and ovarian cancer



Dr Tanya Shaw, St George's University London, UK - AICR grant: £78,584 for 3 years

Worldwide, an estimated 125,000 women die of ovarian cancer each year but the causes are still unknown. One theory is that the constant injury and repair caused by ovulation can lead to cancer. "Every time a woman ovulates an egg is released from one of the ovaries," Dr Shaw explained, "this means that a hole or 'wound' in the layer of cells surrounding the ovary is made, which then heals over the next few days. This happens every month and it is thought that in some women this repeated injury and healing eventually causes the cells to change and become cancerous." Further evidence that supports this hypothesis is the fact that reducing the number of ovulations a woman has during her lifetime, for example through the use of oral contraceptives, decreases their risk of ovarian cancer. Dr Shaw is now using her AICR grant to investigate the damage caused to the ovarian tissue cells when the egg is released and how it is then repaired, including the time taken and any inflammation that may occur. By looking at pre-cancerous changes and ovarian tumours she hopes to understand the relationship between the injury, the healing process and ovarian cancer.

Investigating Wilms tumours – a type of childhood kidney cancer

Dr Andreas Schedl, INSERM U636, France - AICR grant: £175,505 for 3 years

Wilms tumours are a type of kidney cancer affecting children, with around 80 babies born with the condition each year. The tumours can begin when the baby is inside the mother and the kidneys are developing, or they can develop when the child is older, around 3 or 4. The tumours appear to develop because of a problem with certain kidney cells in the developing embryo. The exact causes of Wilms tumours are poorly understood as Dr Andreas Schedl explains: "The genes known to cause Wilm's tumours –WT1 and WTX – work with a particular part of the cells' internal control system which makes sure kidney cells develop properly. When the control system fails to work, perhaps because of damage to the WT1 or WTX genes – the embryo's kidney cells develop incorrectly and start to become a tumour." Dr Schedl is now investigating how the control system works and its role in determining the fate of the embryonic kidney cell in order to understand how Wilm's tumours begin.



Raising money for research

We are extremely grateful to everyone who has helped fund projects across the world in the last year, particularly during such difficult economic times. Raising money is not easy and involves dedication and ingenuity. From people who donate regularly to AICR, to those who take part in events and enter our prize draws, their support is invaluable. Here are some examples of the ways our supporters raise money:

Regular giving

Regular giving is a vital source of income and we want to thank all those who give regularly to AICR by way of a direct debit, standing order or through the workplace via payroll. Their continuing generosity raises almost half of AICR's annual income.

Donations from our prize draws and raffles

AICR has a long and successful track record using prize draws and raffles as a large part of our fundraising effort. Over 220,000 donors receive our sweepstake mailings throughout the year. We also

send regular newsletters updating supporters on the research they are helping to fund. During 2009/10 AICR raised over £5.9 million from prize draws and raffle mailings.

Spotlight Appeal

The Spotlight on Prostate Cancer Appeal was launched in 1998 to raise funds specifically for prostate cancer research. During the 2009/10 year the Spotlight on Prostate Cancer Appeal raised over £518,000 (excluding gift aid and regular giving). Since this appeal began it has raised almost £7.7 million for prostate cancer research allowing us to continue making strides towards tackling this disease.

Next year we are launching a new website www.prostateanswers.org.uk which will be a resource for information about prostate cancer hosted by our Scientific Co-ordinator Dr Mark Matfield. The aim of the site is to answer your questions about any aspect of prostate cancer or prostate cancer research in a friendly and understandable way.

Events

Cancer knows no boundaries, fortunately neither do our supporters...

Every year, hundreds of AICR supporters take part in fundraising events to raise funds for our important cancer research. From running marathons, to trekking up the world's highest mountains; from skydiving to white water rafting – AICR is proud to have some of the most dedicated and passionate fundraisers in the world.

Here are a few who took part in events for us in 2009/10:

David 'Mighty Brightly' Bright

After being personally affected by cancer, David decided to put on his running shoes and raise money for cancer research. He completed a half marathon and decided he was ready for the next step....a place in the London Marathon.

'Along with myself, both my parents have been unfortunate enough to be touched by cancer and in 2007 my Uncle Kevin lost his fight with it. So for me to run for a cancer research charity which funded world-class research into all types of cancer, seemed like a logical step.'



David's wife, Liz, suggested the slogan 'Mighty Brightly' as a possible catchphrase for David's running vest. This instigated a chain of inspiration and ended up with David's friend, Gary, writing a song and making a music video to document David's training progress. David's story received national media coverage, including a feature on BBC television. He successfully completed the marathon in 4 hours and 31 minutes, and raised in excess of £2,500 for AICR.



High flyer Louise Kerry

Louise, 30, was due to take part in a charity parachute jump for AICR last August but sadly had to postpone her jump after being diagnosed with cervical cancer. The mum-of-two had to undergo a radical hysterectomy, but three months later she was given the all-clear. 'After my operation it made me want to do the jump even more. I called it a celebration jump for getting the all-clear'. Louise took to the skies in July, skydiving at 12,000ft in a tandem skydive. 'It was one of the most amazing things I have ever done in my life and feel so proud that I did it for AICR'.

Dave Lennox aka Her Majesty the Queen

Legal Deed Pole Service

Dave, from Aberdeen, got in touch with AICR to say that he would like to do some fundraising - with a difference. In February, Dave launched an online poll to find a 'new name' to raise funds for AICR. Despite having options such as 'Dan Gerous' and 'Batt Mann', there was a clear winner and in April, Dave officially changed his name to 'Her Majesty the Queen'.



The name - suggested by Christine Hamilton - now stands on all of Dave's official papers, from his driving license to his bank cards. 'I have always wanted to do something worthwhile for charity but waited to do something a little bit different. I picked names I felt I

could live with for a year and ones that I thought would raise the most money.'

Dave, who is an NHS worker, says; 'I have to think about how I'm going to answer the phone at work. I think the majority of patients are going to question speaking to 'Her Majesty' so I think I might have to call myself Madge.' Dave raised more than £700 through the online poll.



Online fundraising

The small online team at AICR had another interesting year making the most of new tools and opportunities to keep in touch with supporters, donors, fundraisers and the scientists we are funding. There were many changes in the online world with Facebook and Twitter going from strength to strength, whilst Bebo and MySpace became less popular.



Fundraiser Rene meets AICR Research Fellow Dr Andrew Tee at his lab in Cardiff

One of our major advances was the use of video online as we added footage of our fundraisers talking about why they support AICR and short films of scientists whom we are funding. We even managed to put the two together and have fundraisers interviewing scientists on camera. This allows our supporters around the world to see and hear what other people are doing to raise money for our research and also get a more intimate and visual idea of the work which is being carried out by the dedicated scientists working to make new discoveries.

As well as continuing our popular online competitions and virtual events in Second Life, we were heavily involved in some of the "real world" fundraising events such as the London Marathon and the Leica camera users' book.

Leica camera user's group book

Members of the international Leica user's forum put their talents to the test to create a spectacular volume of photographs in aid of AICR. All members were invited to pay to submit up to three images to be included in a book, published in aid of the charity. The response was staggering and Leica themselves also got behind the Forum's efforts by launching a Twitter campaign: 'Leica for AICR' which generated a further 3000 Euros (£2,482) for AICR.



From left: Andy Barton of the Leica Forum; David Bell, Managing Director of Leica UK; AICR Research Fellow Professor Eric So, from King's College, London and Leica Forum member Bill Palmer.

The resulting Leica User Forum Charity Book 2010 showcases the work of 101 photographers, in 143 photographs. The subjects – people, landscape, architecture, etc – may vary, but the common thread is the appreciation and use of Leica cameras and lenses. So far, nearly 250 of the coffee table books, which received rave reviews in the photographic press, have been sold, raising more than £10,000 for AICR. A special copy of the glossy volume, signed by the heads of both AICR and Leica, was also auctioned.

Leica Forum member Bill Palmer, who came up with the photo book idea, is delighted at how the campaign has developed. He said: "It's great to know that the money we have raised has gone to such a good cause and will help to make a difference."

You can preview and purchase the book for £65 at www.blurb.com/bookstore £5 from each copy sold goes to AICR.

The online world is changing as quickly as ever and new services and opportunities continue to spring up at a dizzying pace. AICR's online team is working hard to keep up-to-date with as many of these as possible and to ensure that AICR's message reaches as large an audience as possible.

Corporate support, trusts and payroll giving



From left: AICR Donor Development Manager Geraldine Long, AICR Chief Executive Norman Barrett, Edith Sands and her husband D. Lindsay Sands, Chairman of David Sands.

Local stores play an important role in the community and are extremely generous in their support of charities and good causes. David Sands Ltd, the convenience store chain, is a magnificent example of that investment in the community. The company has been an active and generous supporter of AICR's work for several years.

Customers and staff from the shops across the chain have supported AICR in a number of different and diverse ways including having our collection boxes on the counters, sharing the proceeds from their plastic bag initiative, and even a sponsored staff bike ride. In 2010, management and staff also nominated AICR to receive an award from Nisa.

We are very grateful to the management of David Sands Ltd, not only for nominating us to receive this award, but also for their continuing support and generosity for our work.

Corporate Partners

AICR strategic partners are companies that support AICR funded research in a number of ways and strive to continue and grow their support year on year. By aligning themselves with our work, companies see a direct benefit to employees & customers and enjoy an ongoing association with our staff.

Corporate Sponsorship

Sponsoring an AICR charity event projects a positive image and provides many benefits for the company, including prominent signage, media and promotional exposure and employee volunteer opportunities. AICR has several events that offer a wide variety of target audiences.

Corporate Social Responsibility (CSR)

Donating much needed funds makes an immediate impact on AICR. Whether given to a specific research project or not, it positions your company as a generous corporate citizen.

To find out how AICR can benefit your company, please contact our Donor Development Manager, Geraldine Long on 01334 477910 or geraldine.long@aicr.org.uk.

Trusts and Foundations

AICR relies on the generous support of many charitable trusts and foundations to help us deliver our aim of saving lives by funding the very best cancer research in the world. In 2009/10 we raised an impressive £85,478 from Trusts and Foundations.

If you have a trust or foundation and are interested in learning more about our work and specific projects which your money could go towards, please contact the Trust Officer Helen Ironside on 01334 477910 or email at Helen.Ironside@aicr.org.uk.

Payroll Giving

Payroll Giving (sometimes known as Give as You Earn) is a great way for employees to give to AICR straight from their pay. Donations are made before any tax deductions, making it one of the easiest and most effective ways to donate.

The table below shows how Payroll Giving donations will benefit both AICR and your employees:

Monthly Pledge	Actual cost to employee (20% rate tax payer)	Actual cost to employee (40% rate tax payer)
£5	£4	£3
£10	£8	£6
£20	£16	£12

As an employer you can take pride in fundraising for AICR without any financial commitment on your part, nor disruption to you or your staff. For more information and to get involved please contact Helen Ironside on 01334 477910 or email Helen.Ironside@aicr.org.uk.

If you have a Payroll Giving scheme in place or would like to set one up, you can operate a matched giving scheme where you as an employer can match £ to £ any donations your employees make to charity. With matched gifts you as a company do not pay any corporation tax on the money you use to match any employee giving.

30th anniversary scientific conference


2010 was AICR's 30th anniversary and to celebrate we hosted a very successful scientific conference in our hometown, St Andrews from 7th until 9th April.

The conference, entitled "Today's Research – Tomorrow's Therapies", was organised to illustrate how developments in basic laboratory based cancer research can feed through to translational studies and the important role of model systems in both areas. It was open to researchers around the world who paid to attend and share their ideas and findings. In total almost 200 delegates attended from 28 countries including China, Denmark, Hong Kong, Israel, Malaysia, Pakistan, Taiwan, USA, Australia and Europe.

The lectures were given by current and previous AICR grant holders and covered the main areas of cancer research that AICR has funded over the past 30 years.



AICR Chairman James Murray and Sir Tim Hunt



Scientists networking over the poster presentations

The keynote lecture was given by Nobel Laureate, Sir Tim Hunt. Entitled 'The Truth about Cancer', this very personal story was much enjoyed and very well received by scientists and lay audience alike. Endorsing AICR's concentration on funding basic cancer research, Sir Tim commented that there are still very basic things we don't understand about cancer and that people's perception of research is often mistaken. "Research is carried out by people trying to understand the world and poking and probing and discovering things they were not looking for". He also celebrated the advances we are making and the increases in survival rates, again sharing a personal story about his mother-in-law who was successfully treated after being diagnosed with a life-threatening brain tumour. Thanks to advances in cancer research, her case was very different to that of his own mother who sadly died from stomach cancer 30 years earlier.

Equally appreciated was a very emotive and motivational speech from Dave Cook, a testicular cancer survivor, on his experiences and the reasons why he raises money for AICR. Research Fellow Dr Andrew Tee from Cardiff University, Wales, then gave an insight into how his AICR fellowship has enabled him to establish a laboratory group and why our supporter's donations are so vital.

There were also dedicated poster sessions where over 130 posters were presented, many from young researchers starting out in their careers.

Innes Barbosa said of the conference "It was touching to hear the speeches of those who faced cancer and survived because of the work we, researchers, develop. These moments made me reflect about my work and my own future aims giving me the strength to continue doing good work. In summary, I think this conference helped me to grow as a scientist."

Imran Ahmad who attended the conference said "It was immediately obvious that AICR funds world class cancer research, with the emphasis on young researchers trying to establish themselves in the field."

Ali Salajegheh also added "My attendance at this conference allowed me the opportunity to network with world leaders in my field which potentially could open up routes for international collaboration in the future."



Dave Cook - cancer survivor & AICR fundraiser

Financial Accounts

Income and Expenditure

	INCOME	2009/10	2008/09	2007/08
Year ended 30th Sept 2010	Donations	15,523,095	15,238,134	15,900,291
	Legacies	1,521,476	1,605,085	1,506,750
	Total voluntary income	17,044,571	16,843,219	17,407,041
	Investment & other income	437,640	525,711	578,454
	Gain/(Loss) on investments	4,360	0	0
	Total income	17,486,571	17,368,930	17,985,495
	LESS EXPENDITURE			
	Fundraising	4,792,474	3,171,744	3,950,255
	Donor Recruitment	1,425,583	1,475,578	2,015,129
	Support & Governance	927,024	920,835	871,251
	Total	7,145,081	5,568,157	6,836,635
	Net income	10,341,490	11,800,773	11,148,860
	LESS OTHER EXPENDITURE			
	Research	8,745,485	8,325,186	8,510,615
	Education	1,791,281	2,324,400	1,553,136
	Support costs	413,112	346,326	266,204
	Total	10,949,878	10,995,912	10,329,955
	Operating surplus/deficit	-608,388	804,861	818,905
	Unrealised gains/(losses) on investments/property	843,458	534,578	-1,571,052
	Total surplus/(deficit) for year	235,070	1,339,439	-752,147
Balance sheet at 30th September 2010	FIXED ASSETS			
	Tangible assets	999,439	1,026,102	1,077,785
	Listed investments	12,935,076	11,063,523	10,325,687
	Total	13,934,515	12,089,625	11,403,472
	CURRENT ASSETS			
	Debtors	1,375,004	1,575,523	1,646,477
	Short term bank deposits	2,743,230	4,801,323	4,235,699
	Cash in bank & in hand	29,056	451,146	252,295
	Total	4,147,290	6,827,992	6,134,471
	CREDITORS			
	Amounts falling due within one year	14,489,601	14,883,455	14,750,089
	Net current liabilities	-10,342,311	-8,055,463	-8,615,618
	Assets less current liabilities	3,592,204	4,034,162	2,787,854
	Long term creditors	7,907,284	8,584,312	8,677,443
	Balance carried forward	-4,315,080	-4,550,150	-5,889,589

Accounts for the five years to 30th September 2010

	2009/10	2008/09	2007/08	2006/07	2005/06
	£000	£000	£000	£000	£000
Total income	17,487	17,369	17,986	18,354	16,610
Appeals & support/governance costs	7,145	5,569	6,837	8,517	5,236
Research/education expenditure	10,950	10,996	10,330	11,853	10,901
Operating surplus/(deficit)	-608	804	819	-2,015	473
Unrealised investment gain/(loss)	843	535	-1,571	-25	662
Total surplus/(deficit)	235	1,339	-752	-2,040	1,135
Tangible assets	999	1,026	1,078	678	684
Investments	12,935	11,064	10,325	12,404	10,853
Net current (liabilities)/assets	-10,342	-8,056	-8,616	-7,887	-3,062
Long term creditors	-7,907	-8,584	-8,677	-10,332	-11,572
Balance carried forward	-4,315	-4,550	-5,890	-5,137	-3,097

Financial accounts

Despite the difficult economic climate AICR's donations and legacies remained robust. Donations were maintained at around £15.5m and legacies at just over £1.5m and our total income was still in line with the previous year at almost £17.5m.

Fundraising costs increased as we strive to build our donor base and maintain our current supporters but education costs were lower than previous years and we spent over £8.7m on research projects during 2009/10.

Thanks to careful investments and planning for our fundraising we ended the year in a strong position looking forward to 2010/11 and we intend to investigate other fundraising opportunities both in the UK and abroad in the near future.

This is a summary of information from the annual accounts. The full annual accounts, which give a detailed overview of our financial affairs and the Auditor's Report are available from our registered office.

Thank you

Scientific Advisory Committee Members

Our thanks go to the members of the Scientific Advisory Committee for their time, expertise and enthusiasm for the bi-annual grant award meetings.

Scientific Advisory Committee 2009-10

Chairman - Professor Alan Clarke, Cardiff University, Wales

Professor Bruno Amati, European Institute of Oncology, Milan, Italy

Dr Axel Behrens, CRUK London Research Institute, England

Professor Pierre van der Bruggen, Ludwig Institute, Brussels, Belgium

Professor Antony Carr, University of Sussex, England

Professor Lena Claesson-Welsh, Uppsala University, Sweden

Dr Simon Cook, Babraham Institute, Cambridge, England

Professor Dominique Bonnet, CRUK London Research Institute, England

Professor Nicola Curtin, University of Newcastle upon Tyne, England

Professor Jeff Evans, Beatson Institute for Cancer Research, Glasgow, Scotland

Professor Ron Hay, University of Dundee, Scotland

Dr Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

Professor Peter Lichter, German Cancer Research Centre, Heidelberg, Germany

Professor Laura Machesky, Beatson Institute for Cancer Research, Glasgow, Scotland

Dr Angel Nebreda, National Cancer Research Centre, Madrid, Spain

Professor Neil Perkins, University of Newcastle, England

Dr Jonathan Pines, Gurdon Institute, Cambridge, England

Professor Alan Rickinson, University of Birmingham, England

Dr Mark Searcey, University of East Anglia, Norwich, England

Professor Michael Seckl, Imperial College, London, England

Professor Hugues de The, University of Paris, France

Professor Michael Threadgill, University of Bath, England

Professor Bart Vanhaesebroeck, Barts & The London School of Medicine & Dentistry, London, England

Professor Ulla Vogel, National Research Centre for the Working Environment, Copenhagen, Denmark

Professor Harry Vrieling, Leiden University Medical Centre, The Netherlands

AICR is extremely grateful to everyone who has made our work possible. We would particularly like to thank our external fundraising agencies, our Patron the Earl of St Andrews, our Vice-Presidents, the Board of Directors, our Scientific Advisory Committee and all of our suppliers and agencies who have helped us throughout the year and beyond.



AICR is a member of the Association of Medical Research Charities (AMRC). AMRC members aim to follow the highest standards of accountability in medical and health research funding, and are required to use independent peer review in the allocation of all grants and awards for research. AICR is also a member of the Institute of Fundraising and abides by the Institute's Code of Practice to ensure the highest professional standards in fundraising.

Legacies

As a charity that relies almost entirely on voluntary donations, the income generated from legacies is very important to us. Unfortunately, we are often unaware of our donors' intentions and therefore unable to thank them during their lifetime. We would like to acknowledge the generosity of those of our supporters who sadly died and left a legacy to AICR during 2009-2010.

Mr S A J Ablewhite
Mr T F Andrews
Mr W J Austin-Clark
Mr C E Barnes
Ms B Blue
Mr R C Blunt
Mr C H Bromley
Miss D M Carnochan
Dr N S Chaudhuri
Ms N J Clemance
Mr R Cole
Mrs M M Derby
Mr G Doore
Mrs G W Doore
Mrs J Eveling
Mr D W Field
Mrs A L Foster
Mr E Fraser
Dr F J Glen
Ms A M Grundy

Mrs E M C Hallowell
Mr J A Hangartner
Mr D R Harrison
Mr H G Hey
Miss M G Johnson
Miss M G Knowles
Mrs N Lacey
Mrs J E Land
Mr J C A M Lyons
Mr D R MacRitchie
Miss M R Milbank
Mrs M A Nisbet
Mrs J O'Brien
Mr I J B Ogilvie
Mrs P A Parker
Mr M A Pearce
Mr J M Perry
Miss E Ribton-Turner
Mr A C H Riley
Dr S Rowell

Rev J T Sammons
Miss N F J Shield
Mrs W Shorrock
Mrs C E Smith
Mrs E M R Stern
Mrs M Stone
Mr A G Stevenson
Mrs P M Stott
Miss E F Tame
Ms D E Townsend
Mrs D M Turnbull
Mr Harry Walton
Miss H P J Wanliss
Mrs E Wheatland
Mrs S R Whitehouse
Mrs M M Wilkinson
Ms E M E Williams
Mrs M E F Winters





AICR

***Cancer knows no boundaries.
Fortunately, neither do we.***

Association for International Cancer Research

Madras House
St Andrews
Fife
KY16 9EH

T: +44 (0)1334 477910
F: +44 (0)1334 478667
E: aicr@aicr.org.uk
www.aicr.org.uk

*Patron: The Earl of St Andrews
Registered in Scotland, No: 152991 Charity No: SC022918*

Directors:

Mr James C Murray (Chairman), Professor C Simon Herrington, Mr John F Matthews OBE,
Mr James Ogilvy, Mr Andrew Orme, Professor C Michael Steel, Mrs Maureen Thomson, Professor John A Wyke